Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and relaxing because that oh-so-familiar routine of meetings, deadlines, conference calls, and the like has, of course, returned. Before we continue, though, we want to apologize for the late start. We were sidetracked by a bit of shoveling — there were mounds of snowing blanketing the Pharmalot campus and then a quick story to post, which leads off the list of items today. In any event, time for a cup of stimulation. Hope all goes well today and you conquer the world …

Eli Lilly (LLY) is introducing a new version of insulin called Lispro at half the list price as drug makers struggle with mounting criticism over the cost of prescription drugs, although insulin costs have generated particular anger among consumers, STAT writes. The new so-called authorized generic version of the Humalog insulin will sell for $137.35 a vial, while the list price of a five-pack of KwikPens will be $265.20. Lispro should be more affordable to the uninsured or those with high-deductible insurance plans, whose copays are typically tied to list prices.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy